Los Angeles, CA Clinical Trials Report — April 2026

For Los Angeles residents considering participation in clinical research, April 2026 presents a critical window for those looking to join studies before enrollment concludes. Across the city, 146 clinical trials are slated to close within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 33 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly.

Impending Deadlines for Specific Conditions

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cancers, mental health conditions, and chronic diseases are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (5 trials)
• Anxiety (5 trials)
• Fear (3 trials)
• Leukemia (3 trials)
• Anatomic stage iii breast cancer ajcc v8 (3 trials)
• Head and neck squamous cell carcinoma (3 trials)
• Diabetic foot ulcer (2 trials)
• Colon cancer (2 trials)
• Diabetic foot (2 trials)
• Advanced breast cancer (2 trials)

This month, Los Angeles saw the opening of 10 new clinical trials, a decrease from the 29 trials that launched in March 2026. Despite this dip in new openings, Los Angeles continues to be a significant hub for medical research, with a total of 1,872 clinical trials currently recruiting across 789 research facilities.

Spotlight on New Research Opportunities

April brings several notable new trials to Los Angeles, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Incyte Corporation is launching NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of a new combination therapy for metastatic pancreatic cancer.
• Loyola Marymount University is sponsoring NCT07546604, "Feasibility and Effectiveness of Gamified Digital Intervention to Prevent Alcohol and Mental Health Risks." This study, aiming for 1,752 participants, evaluates a novel smartphone application for its impact on alcohol consumption, alcohol-related problems, and psychological well-being. Participants are biological females between the ages of 18 and 59 years.
• The University of California, San Francisco is leading NCT07513623, "Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II." This Phase 2 study, designed for 117 participants, compares antiviral treatment strategies for cytomegalovirus (CMV) anterior uveitis, a viral infection causing eye inflammation in immunocompetent adults.
• Also from the University of California, San Francisco, NCT07538336, "Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction," is a Phase 2 study for 40 participants. It tests the medication emapalumab for its potential to help lung transplant recipients experiencing acute lung allograft dysfunction (ALAD), a serious complication.

New trials this month are exploring a range of conditions, including alcohol prevention, anterior uveitis, autism, and various stages of esophageal and gastric cancer. Behavioral trials account for the majority of new studies, with 5 new behavioral trials, followed by 3 drug trials. For individuals without a specific medical condition, there are significant opportunities to contribute. 4 of the new trials launched this month are actively seeking healthy volunteers. Across Los Angeles, a total of 189 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Participation in clinical trials is open to a diverse range of individuals. Of the 10 new trials launched this month, 8 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is specifically designed for female participants, and 2 new trials include children. Academic institutions continue to play a vital role in Los Angeles's research ecosystem, with the University of California, San Francisco and the University of Southern California sponsoring the majority of new trials this month. Industry sponsors like Incyte Corporation are also driving significant research efforts.

Los Angeles's Leading Research Hubs

Los Angeles is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Cedars-Sinai Medical Center (165 trials)
• Children's Hospital Los Angeles (111 trials)
• Cedars Sinai Medical Center (110 trials)
• University of California, Los Angeles (90 trials)
• University of Southern California (87 trials)
• USC / Norris Comprehensive Cancer Center (86 trials)
• University of California Los Angeles (70 trials)
• Los Angeles General Medical Center (64 trials)
• UCLA / Jonsson Comprehensive Cancer Center (59 trials)
• UCLA (54 trials)
• Kaiser Permanente Los Angeles Medical Center (50 trials)

These institutions offer a broad spectrum of research, from oncology at Cedars-Sinai and USC / Norris Comprehensive Cancer Center, to pediatric care at Children's Hospital Los Angeles, and diverse medical fields across the University of California, Los Angeles campuses.

Broadening Your Search: Nearby Options

While Los Angeles offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within California. Cities with active trials include San Francisco (21 trials), San Diego (6 trials), Duarte (5 trials), Glendale (5 trials), Palo Alto (5 trials), Los Alamitos (4 trials), La Jolla (4 trials), and Orange (3 trials).

As we move further into spring, the focus will remain on the ongoing enrollment in these significant trials and the continued exploration of new therapeutic strategies, with Los Angeles's robust research community at the forefront of medical innovation.